Alzheimer's Dementia
Conditions
Interventions
Not applicable.
Sponsors
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co. Inc.
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Body Mass Index (BMI) between >= 18 and
Exclusion criteria
Exclusion criteria: History of clinical signifiant endocrine, GI, cardiovasculair, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases. Participants with a remote history of uncomplicated medical events (eg, uncomplicated kidney stones, as defined as spontaneous passage and no recurrence in the last 5 years, or childhood asthma) may be enrolled in the study at the discretion of the investigator. Mentally or legally incapacitated, has significant emotional problems at the time of screening visit or expected during the conduct of the study or has a history of clinically significant psychiatric disorder in the last 5 years. Participants who have had situational depression may be enrolled in the study at the discretion of the investigator. Further criteria apply, see protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective: To evaluate the effect of single oral doses of MK-1167 on glutamate metabolism in the prefrontal cortex using sel POCE 13C-MRS Hypothesis: The mean fractional enrichment (FE) of glutamate increases above baseline levels for at least one dose level of MK-1167 | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective: To evaluate the effect of single oral doses of MK-1167 on glutamine metabolism in the prefrontal cortex using sel POCE 13C-MRS Hypothesis: The mean FE of glutamine increases above baseline levels for at least one dose level of MK-1167 To evaluate the safety of single doses of MK-1167 in healthy adult participants | — |
Countries
Netherlands
Outcome results
None listed